U. In this paper, the author analyzes the characteristics of. M amp; Aacute; s. to be exact, the current invention and amp; oacute; n refer to C amp; eacute; Lulas t.TRANSFECTED / TRANSDUCED WITH AN ANTI-GENE UNION RECEIVER THAT IS ATTRACTED BY THE UNION / SPECIFIC INTERACTION WITH THE DOMAIN FC MUTATED FROM THERAPEUTIC ANTIBODIES. IN ADDITION, THE INVENTION IS REFERRED TO A KIT THAT INCLUDES THE T-CELLS OF THE INVENTION AND / OR MOLEACULES OF NUCLEIC ACIDS,VECTORS EXPRESSING AN ANTI-GENE RECEIVERS OF THE PRESENT INVENTION AND ONE OR MORE ANTIBODIES WITH TUMORAL TARGET THAT INCLUDE A MUTATED FC DOMAIN. THE INVENTION FURTHER PROVIDES THE PRODUCTION AND USE OF CEULAS T IN A METHOD FOR THE TREATMENT OF PARTICULAR DISEASES, AS WELL AS TUMORAL ANTIBODIES. AS PHARMACEUTICAL COMPOSITIONS / MEDICINES INCLUDING CE TITLES AND / OR THERAPEUTIC ANTIBODIES,C amp; eacute; Lulas t must combine CI amp; oacute; n M amp; Aacute; s antibody with Diana tumor therapy and amp; eacute; uticos, including Fc domain with uni amp mutation; oacute; n reduction to FC. lt; / P gt receiver;<;p>;LA PRESENTE INVENCIÓ;N SE REFIERE DE MANERA GENERAL A RECEPTORES DE UNIÓ;N A ANTÍ;GENO CAPACES DE UNIÓ;N ESPECÍ;FICA A DOMINIOS FC MUTADOS CON UNIÓ;N A RECEPTOR FC REDUCIDA Y CÉ;LULAS T QUE EXPRESAN DICHOS RECEPTORES DE UNIÓ;N A ANTÍ;GENO. MÁ;S EXACTAMENTE, LA PRESENTE INVENCIÓ;N SE REFIERE A CÉ;LULAS T, TRANSFECTADAS/TRANSDUCIDAS CON UN RECEPTOR DE UNIÓ;N A ANTÍ;GENO QUE RESULTA ATRAÍ;DO POR LA UNIÓ;N/INTERACCIÓ;N ESPECÍ;FICA CON EL DOMINIO FC MUTADO DE ANTICUERPOS TERAPÉ;UTICOS. ADEMÁ;S, LA INVENCIÓ;N SE REFIERE A UN KIT QUE COMPRENDE LAS CÉ;LULAS T DE LA INVENCIÓ;N Y/O MOLÉ;CULAS DE Á;CIDOS NUCLEICOS, VECTORES QUE EXPRESAN RECEPTORES DE UNIÓ;N A ANTÍ;GENO DE LA PRESENTE INVENCIÓ;N Y UNO O MÁ;S ANTICUERPOS CON DIANA T